Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up

Published:2015-01-13 Issue:10 Volume:121 Page:1637-1644
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Cortes Jorge E.¹,Kantarjian Hagop M.¹,Rea Delphine²,Wetzler Meir³,Lipton Jeffrey H.⁴,Akard Luke⁵,Khoury H. Jean⁶,Michallet Mauricette⁷,Guerci-Bresler Agnès⁸,Chuah Charles⁹,Hellmann Andrzej¹⁰,Digumarti Raghunadharao¹¹,Parikh Purvish M.¹²,Legros Laurence¹³,Warzocha Krzysztof¹⁴,Baccarani Michele¹⁵,Li Elizabeth¹⁶,Munteanu Mihaela¹⁷,Nicolini Franck E.¹⁸¹⁹

Affiliation:

1. University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Adult Hematology; Saint Louis Hospital; Paris France

3. Roswell Park Cancer Institute; Buffalo New York

4. Princess Margaret Hospital; Toronto Canada

5. Indiana Blood and Marrow Transplantation Center; Indianapolis Indiana

6. Emory University School of Medicine; Atlanta Georgia

7. Hematology Department; Centre Hospitalier Lyon Sud; Pierre Benite France

8. Brabois Hospital, Vandoeuvre-les-Nancy; France

9. Singapore General Hospital, Duke-National University of Singapore Graduate Medical School; Singapore

10. Medical University of Gdansk; Gdansk Poland

11. Nizam's Institute of Medical Sciences; Hyderabad India

12. Indian Cooperative Oncology Network; Mumbai India

13. Archet Hospital; Nice France

14. Institute of Hematology and Transfusion Medicine; Warsaw Poland

15. University of Bologna; Bologna Italy

16. PharmaStat LLC; Newark California

17. Teva Branded Pharmaceutical Products R&D; Frazer Pennsylvania

18. Hematology Department 1G, Centre Hospitalier Lyon Sud; Pierre Benite France

19. National Institute of Health and Medical Research 1052, Leon Berard Center; Lyon France

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference28 articles.

1. The molecular biology of chronic myeloid leukemia;Deininger;Blood,2000

2. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance;Kantarjian;Ann Intern Med,2006

3. Molecular biology of bcr-abl1-positive chronic myeloid leukemia;Quintas-Cardama;Blood,2009

4. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience;Kantarjian;Blood,2012

5. Ponatinib in refractory Philadelphia chromosome-positive leukemias;Cortes;N Engl J Med,2012

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy;Frontiers in Oncology;2024-07-29

2. Chronic myeloid leukaemia: Biology and therapy;Blood Reviews;2024-05

3. BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach;Current Oncology Reports;2024-02-10

4. 25 years of experience in the treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: results, opportunities, questions;Meditsinskiy sovet = Medical Council;2024-01-17

5. Do Naturally Modified Nucleotides Contribute to Stabilizing Complexes between Ribosomes and Small Molecules? A Case Study with the Antitumor Drug Homoharringtonine;ChemMedChem;2023-09-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3